Intra-Cellular Therapies (“ITCI”) Stock Soars While Key Clinical Data Not Presented to Shareholders Looks Highly Disappointing

(July 15th, 2015) Biotech stocks have been on fire. And for good reason as numerous life-saving discoveries have come out of small, previously-unknown firms, making their owners rich many times over. But beneath the surface, a number of troubling drug development companies have caught the attention of investors with clinical data that’s dubious at best. With seemingly endless amounts of optimism, these biotech stocks have ridden the wave of investor enthusiam even when the data doesn’t look as promising as the market caps seem to indicate.

Read more

All You Ever Wanted to Know About Retrophin But Were Afraid to Ask

(June 2nd, 2014) Humans, like atoms, abhor unsteady states of existence. Just like electron transport gravitates towards a steady-state, people gravitate towards peaceful lands and away from battleground areas. Read more

Know What to Buy When Putin Comes Knocking

So Putin rolls a bunch of tanks up to the Ukrainian border and the market slides a percent or so. In any other market that would be considered a yawn. But here in the good ‘ol US of A, where the average active investor can barely remember the dog days of ’08, few traders seem to have the skill set necessary to maneuver in a down market. Having done this for 20+ years, I thought it would be helpful to share my trading tips for when war comes knocking.
Read more

Little Bear Investments LLC Participates in Caprius, Inc. $4.5mm Private Placement

Thursday February 17, 2005

NEW YORK, February 17 — Little Bear Investments LLC (“Little Bear”) announced today that it has participated in a $4.5 million private placement to purchase common stock and warrants of Caprius, Inc. (“CAPR”). Laidlaw & Co. (UK) Ltd., a registered NASD broker-dealer, acted as the placement agent in the private placement.

“This private placement gives Caprius a stronger balance sheet and the funds it needs to market and grow its revolutionary SteriMed product”, commented Mr. Zachary Prensky, Managing Director of Little Bear. “It is this type of transaction where the company’s balance sheet is restructured that we at Little Bear are focused on deploying capital.”

About Caprius, Inc.

Caprius, Inc., headquartered in Fort Lee, NJ, is engaged in manufacturing proprietary equipment for on-site medical waste disposal through its subsidiary, M.C.M. Environmental Technologies, Inc (MCM). The Company’s SteriMed units simultaneously shred and disinfect regulated medical waste, reducing its volume up to 90%, and rendering it harmless for disposal as ordinary waste. The SteriMed System is environmentally-friendly and efficiently disinfects the infectious clinical waste, including, among others, sharps, dialyzers, blood lines, bandages, plastic tubing and glass, in a 15 minute cycle. The MCM patented technology is an alternative to hauling and incinerating medical waste. In the U.S., medical waste is a $3 billion market. More information on the Company and MCM can be found at or

About Little Bear

Little Bear Investments, located in the heart of Midtown Manhattan, is a merchant bank that focuses on investing in both public and private companies. Our broad range of investment experience includes: tender offers, private placements, PIPE’s, reverse mergers and bankruptcy auctions. Little Bear also offers financial, operational and strategic advisory services. Working with companies large and small, we bring the same disciplined approach to our clients as we do to businesses in which we have deployed our own capital.

If you have any questions regarding this press release, please contact us at 212-946-2736.

” Concentration is my motto – first honesty, then industry, then concentration. ” Andrew Carnegie